These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1906862)

  • 1. Single daily dosing of amikacin in an in-vitro model.
    Dudley MN; Zinner SH
    J Antimicrob Chemother; 1991 May; 27 Suppl C():15-9. PubMed ID: 1906862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bacteriostatic activity of azlocillin, gentamycin, amikacin singly or in combination on 200 strains of Pseudomonas aeruginosa].
    Texier-Maugein J; Fourche J; Mormede M; Mazaud C; Bébéar C
    Pathol Biol (Paris); 1986 May; 34(5):415-8. PubMed ID: 3095774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model.
    McGrath BJ; Lamp KC; Rybak MJ
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1931-7. PubMed ID: 8239608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
    Cappelletty DM; Kang SL; Palmer SM; Rybak MJ
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro models for the study of combination antibiotic therapy in neutropenic patients.
    Zinner SH; Dudley M; Blaser J
    Am J Med; 1986 Jun; 80(6B):156-60. PubMed ID: 3728526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: effect of simultaneous versus staggered administration in an in vitro model of infection.
    Dudley MN; Blaser J; Gilbert D; Mayer KH; Zinner SH
    J Infect Dis; 1991 Sep; 164(3):499-506. PubMed ID: 1908000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of single-agent therapy with azlocillin, ticarcillin, and amikacin and beta-lactam/amikacin combinations for treatment of Pseudomonas aeruginosa bacteremia in granulocytopenic rats.
    Johnson DE; Thompson B
    Am J Med; 1986 May; 80(5C):53-8. PubMed ID: 3636060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Value of bactericidal curves in the optimal selection of a beta-lactam-aminoglycoside combination on Pseudomonas aeruginosa. In vitro study of 40 strains of Pseudomonas aeruginosa isolated in pediatric intensive care units].
    Lambert-Zechovsky N; Bingen E; Guihaire E; Nancy C; Mercier JC; Beaufils F
    Presse Med; 1986 Dec; 15(46):2309-12. PubMed ID: 2949273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of once- versus twice-daily dosing of nebulized amikacin in an in vitro Hollow-Fiber Infection Model against 3 clinical isolates of Pseudomonas aeruginosa.
    Heffernan AJ; Sime FB; Naicker S; Andrews K; Ellwood D; Guerra-Valero Y; Wallis S; Lipman J; Grimwood K; Roberts JA
    Diagn Microbiol Infect Dis; 2021 Jun; 100(2):115329. PubMed ID: 33714790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ciprofloxacin, azlocillin, ceftizoxime and amikacin alone and in combination against gram-negative bacilli in an infected chamber model.
    Bamberger DM; Peterson LR; Gerding DN; Moody JA; Fasching CE
    J Antimicrob Chemother; 1986 Jul; 18(1):51-63. PubMed ID: 3093445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activities of ureidopenicillins alone and in combination with amikacin and three cephalosporin antibiotics.
    Moody JA; Peterson LR; Gerding DN
    Antimicrob Agents Chemother; 1984 Aug; 26(2):256-9. PubMed ID: 6435516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergy of azlocillin with aminoglycosides.
    Chin NX; Neu HC
    J Antimicrob Chemother; 1983 May; 11 Suppl B():33-8. PubMed ID: 6413482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of azlocillin, ceftizoxime, cefoxitin, and amikacin alone and in combination against Pseudomonas aeruginosa in a neutropenic-site rabbit model.
    Peterson LR; Gerding DN; Moody JA; Fasching CE
    Antimicrob Agents Chemother; 1984 May; 25(5):545-52. PubMed ID: 6329087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Azlocillin plus amikacin: an alternative therapy for sepsis caused by resistant staphylococci?].
    Hernández ME; Ramos MJ; Ferrer NF
    Rev Panam Salud Publica; 2004 Nov; 16(5):315-9. PubMed ID: 15729980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-survival studies for quantifying effects of azlocillin and tobramycin on Pseudomonas aeruginosa.
    McFarland MM; Scott EM; Li Wan Po A
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1271-6. PubMed ID: 8092825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients.
    Flaherty JP; Waitley D; Edlin B; George D; Arnow P; O'Keefe P; Weinstein RA
    Am J Med; 1989 Nov; 87(5A):278S-282S. PubMed ID: 2686429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo efficacy of azlocillin and amikacin versus ciprofloxacin with and without amikacin in experimental right-sided endocarditis due to Pseudomonas aeruginosa.
    Bayer AS; Kim KS
    Chemotherapy; 1986; 32(4):364-73. PubMed ID: 2942342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against Pseudomonas aeruginosa in a Dynamic
    Heffernan AJ; Sime FB; Sarovich DS; Neely M; Guerra-Valero Y; Naicker S; Cottrell K; Harris P; Andrews KT; Ellwood D; Wallis SC; Lipman J; Grimwood K; Roberts JA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32660986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro comparison of N-formimidoyl thienamycin (MK0787) and Azlocillin with three aminoglycosides and ticarcillin against Pseudomonas aeruginosa.
    Matzkowitz AJ; Baltch AL; Smith RP; Sutphen NT; Hammer MC; Conroy JV
    Antimicrob Agents Chemother; 1982 Apr; 21(4):685-7. PubMed ID: 6805426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bactericidal kinetics of an in vitro infection model of once-daily ceftriaxone plus amikacin against gram-positive and gram-negative bacteria.
    Scaglione F; Dugnani S; Demartini G; Arcidiacono MM; Cocuzza CE; Fraschini F
    Chemotherapy; 1995; 41(4):239-46. PubMed ID: 7555203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.